News | CT Angiography (CTA) | October 16, 2018

CT Offers Non-Invasive Alternative for Coronary Disease Treatment Planning

Heart teams find CT angiography equally beneficial to angiography when deciding between treatment options

CT Offers Non-Invasive Alternative for Complex Coronary Disease Treatment Planning

October 16, 2018 — A new study published in the European Heart Journal[1] shows computed tomography (CT) can be a useful aid in heart team decision-making for complex coronary disease. Results also suggest the state-of-the-art imaging technology may offer a non-invasive diagnostic alternative to conventional coronary angiography. Coronary artery disease (CAD) and its complications are a leading cause of death throughout the world.[2] According to therapeutic guidelines, left main or three vessel diseases represent the most severe, high-risk CAD cases, often requiring coronary bypass graft surgery (CABG) or percutaneous coronary intervention (PCI) as treatment.[3]

The international, multicenter SYNTAX III Revolution trial – conducted by Cardialysis on behalf of the European Cardiovascular Research Institute (ECRI) – included 223 subjects with diagnosed left main or three vessel disease. Each patient was diagnosed using conventional, invasive angiography and subsequently received a multislice CT scan on the 512-slice GE Healthcare Revolution CT. Data from each subject was evaluated by two randomized heart teams – each made up of an interventional cardiologist, cardiac surgeon and radiologist – to make a treatment recommendation of CABG, PCI or either. One heart team made treatment recommendations based only on the coronary CT angiography (CTA) imaging, and the other made treatment recommendations using angiography. Based on the trial’s findings, the treatment decisions between the two randomized heart teams were in almost perfect agreement (Cohen’s kappa of 0.82). These results highlight the potential of CT to not only diagnose coronary disease, but also assist in subsequent heart team decision-making.

“The implications of these trial results for the future are tremendous,” said Prof. Patrick W. Serruys, principal investigator and study chairman. “In the next five to ten years, with its increasing accuracy, I think we are going to see the new generation of multislice CT scans play an increasingly important role in diagnosing and treating CAD. It will take time and it will take multiple trials, but the results of our SYNTAX III trial suggest a promising, real change in our practice.”

This change could include streamlining the care pathway. The multislice CT scan offers an easier, less-invasive patient experience; takes less time; and a provides a clear, comprehensive anatomical picture to assist clinicians with diagnoses and treatment recommendations. Serruys suggests the CT’s potential as a diagnostic tool for complex coronary disease could enable cath labs to transition from diagnostic to interventional suites that concentrate on the significant load of coronary and structural heart disease patients.

“Technological advancements are drastically improving medical insights and opportunities as well as patient care,” continued Serruys. “The ability to capture an image of the whole heart in one beat with the multislice CT and then see the coronary artery from multiple views is very appealing to interventional cardiologists and surgeons. The images provided by the multislice CT are a bonus that can help surgeons plan and mentally prepare to treat patients in the interventional suite.”

After reviewing the trial’s results, 84 percent of surveyed[4] cardiac surgeons agreed planning and executing surgery based on the multislice CT scan is viable. Cardialysis will follow up the SYNTAX III Revolution trial with a new study, CABG Revolution, to test the safety of CABG surgery for left main or three vessel disease using only the anatomy and function described by the multislice CT scan.

The SYNTAX III trial is an investigator-driven study sponsored by the ECRI and funded by research grants from GE Healthcare and HeartFlow Inc.

For more information: www.academic.oup.com/eurheartj

 

References

[1] Collet C., Onuma Y., Andreini D., et al. Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease. European Heart Journal, Oct. 11, 2018. https://doi.org/10.1093/eurheartj/ehy581

[2] Gersh B.J, Sliwa K., Mayosi B.M., Yusuf S. “Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications.” European Heart Journal. 2010 Mar; 31(6):642-8.https://www.ncbi.nlm.nih.gov/pubmed/20176800/

[3] Mohr F.W., Morice M.C., Kappetein A.P., et al. “Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.” Lancet. 2013 Feb 23; 381(9867):629-38. https://www.ncbi.nlm.nih.gov/pubmed/23439102/

[4] Cardialysis. “Theoretical Feasibility of Planning CABG based only on Coronary CTA and FFRCT: A Survey of the Surgeons involved in the Randomized Syntax III Revolution Trial.” 2018 Jan. Unpublished raw data.

Related Content

Sponsored Content | Case Study | Enterprise Imaging | November 16, 2018
Centricity Clinical Archive Analytics uses Microsoft Azure and Power BI Embedded to derive intelligence from the data
Feature | November 16, 2018 | By Greg Freiherr
For the first time at the RSNA meeting, vendors of interventiona
Podcast | Interventional Radiology | November 16, 2018
For the first time at the RSNA meeting, vendors of interventional products will have a dedicated area in which to dis
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Canon Medical Receives FDA Clearance for Vantage Orian 1.5T MRI
Technology | Magnetic Resonance Imaging (MRI) | November 15, 2018
Canon Medical Systems USA Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on its new...
GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
News | Enterprise Imaging | November 14, 2018
Konica Minolta Healthcare Americas Inc. will showcase new features and tools for the Exa Enterprise Imaging platform at...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
SuperSonic Imagine Introduces Aixplorer Mach 30 Ultrasound at The Liver Meeting
Technology | Ultrasound Imaging | November 14, 2018
SuperSonic Imagine recently exhibited at The Liver Meeting, held Nov. 9-13 in San Francisco, where the company...